Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/8/18 → 3/31/21 |
Funding
- Alnylam Pharmaceuticals, Inc: $235,503.23
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias
- Anderson, Karl (PI)
Project: Other project